North America Mycoplasma Testing Market

North America Mycoplasma Testing Market Size

The North America Mycoplasma Testing Market was valued at USD 234.97 million in 2023. The North America Mycoplasma Testing Market is expected to have 11.5 % CAGR from 2024 to 2032 and be worth USD 625.87 million by 2032 from USD 261.99 million in 2024.

MARKET DRIVERS

Factors such as high R&D expenditure by biopharmaceutical companies, increase in government initiatives and research, high degree technological advancements, along with demand for rapid, accurate & affordable tests and increase in contamination of cell cultures further stimulate the mycoplasma market.

The other factor includes the efficiency of polymerase chain reaction tests that is increasing application in clinical diagnostics, the increasing demand for personalized and precision medicine, and technological advancements and applications in drug development.

Mycoplasma infection is complex to see under a microscope and requires specific tests to be detected. Infection can have an acute impact on experimental work depending on the species present. Mycoplasma organisms can affect cell growth, teratogenic, metabolism, and response to chemotherapy. Increased research activity by pharmaceutical and biotechnology companies, increased government support and funding for research activities, and growing contamination of cell cultures around the world are the few factors responsible for the high CAGR market for the upcoming forecast period.

Developments in techniques such as Polymerase Chain Reaction (PCR), Enzyme Immunoassay (ELISA), Enzyme Reaction, and DNA Staining during the pandemic have increased the growth rate. The polymerase chain reaction (PCR) is very popular and is expected to have the highest CAGR for the forecast period. Factors that can be attributed to the popularity of PCR are the precision, speed, and flexibility that this technique offers in life science research.

MARKET RESTRAINTS

However, there are some strict government regulations in several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major obstacles to the growth of the mycoplasma testing market.

Factors such as the lack of trained professionals, physicians and the lack of standards and protocols are limiting the growth of the market. For optimum effectiveness, the mycoplasma testing procedure should be performed by trained professionals with sufficient knowledge of the nuances of this area. Handling the instruments used in mycoplasma testing also requires experience and professionals. Hence, the lack of a sufficiently skilled workforce is hampering the growth of the Mycoplasma Testing market.

Mycoplasma organisms can affect various cellular responses and can give false results as they are techniques sensitive. Hence care should be taken to check for the presence of Mycoplasma in cell banks and biotechnology labs. Otherwise, it can further spoil cell culture-based research, which is challenging the growth rate of the market.

This research report on the North America Mycoplasma Testing Market has been segmented and sub-segmented into the following categories

SEGMENTAL ANALYSIS

By Product Insights

• Kits & Reagents

• Instruments

• Services

By Technique Insights

• PCR

• ELSA

• Direct Assays
• Indirect Assays
• Microbial Culture Techniques
• Enzymatic Methods
• DNA Staining

By Application Insights

• Cell Line Testing

• Virus Testing

• End-Of-Production Cell Testing
• Others

By End-User Insights

• Pharmaceutical Companies

• Contract Research Organizations

• Academic Research Institutes
• Cell Banks

Country Level Analysis

• US
• Canada
• Rest of North America.

The North American region had the largest share of the global market in 2023 and is anticipated to continue its domination in the worldwide market throughout the forecast period owing to the advancements in the healthcare sector and increased healthcare expenditure. The U.S. dominated the

North American market in 2023 and is expected to grow at a promising CAGR in the coming years owing to the growing number of mergers and acquisitions and increased awareness programs about mycoplasma diseases, the growing number of mycoplasma cases, particularly Mycoplasma pneumonia infections affecting the upper and lower respiratory tracts. Symptoms include cough, fever, and headache, with nearly 2 million reported cases in the US annually. Canada is another noteworthy regional market for mycoplasma testing in the North American region with numerous laboratories and clinical trial centers dedicated to mycoplasma testing. Health Canada adheres to specific approval regulations for mycoplasma testing devices and liquids.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Promising Companies leading the North America Mycoplasma Testing Market Profiled in the Report are PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, WuXi AppTec.,